RxDoctor Payments Data

John Lewis, MD

Glaucoma Specialist · Mesa, AZNPI 1851364814

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $46,852 of the $60,558 with a category attached, or 77.4%. 14 manufacturers reported payments, led by Aerie Pharmaceuticals, Inc. at 40.9% of the total. Reporting peaked in 2019 at $18,719 and has fallen 77.5% since, to $4,205 in 2025.

$60,558in general payments, 2019–2025

Across 302 payments — averaging $200.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Aerie Pharmaceuticals, Inc.$25K
  • Bausch & Lomb Americas Inc.$15K
  • AbbVie$15K
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$3K
  • Alcon$936
  • Novartis$324
  • plus $835 from 8 others

What the payments were for

  • Consulting fees$2,3954%
  • Speaking & faculty fees$46,85277%
  • Travel & lodging$3,5446%
  • Food & beverage$7,76813%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

Too few glaucoma specialist providers in Arizonato place this figure against a meaningful peer group, so we don't.

Medicare billing

Part B allowed, 2024
$295,536
Medicare patients
714
Services billed
3,262

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost946$524,571
VyzultaLatanoprostene Bunod255$135,874
RocklatanNetarsudil Mesylat/Latanoprost209$127,062
CombiganBrimonidine Tartrate/Timolol253$120,240
RhopressaNetarsudil Mesylate151$94,587
Alphagan PBrimonidine Tartrate113$46,703
SimbrinzaBrinzolamide/Brimonidine Tart113$35,486
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol99$24,760
Brinzolamide107$18,470
Travoprost133$17,638
Latanoprost1,462$16,623
Brimonidine Tartrate626$12,305
Dorzolamide Hcl557$11,270
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat586$8,842
Timolol Maleate781$8,324

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Combigan, Alphagan P$15,364$691,5141,312 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$24,761$221,649360 claims
Bausch & Lomb Americas Inc.Vyzulta$15,441$135,874255 claims
AlconSimbrinza$936$35,486113 claims
NovartisTravatan Z$324$4,88216 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few glaucoma specialist providers in Arizonaon file to place this against a meaningful peer group, so we don't.

Other glaucoma specialist in Mesa

See the full list for Arizona

Where these figures come from

Is this you, or does something look wrong? →